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Experimental "allergic" encephalomyelitis (EAE) can be produced in many 
mammals and birds by the injection of a  vaccine containing mammalian or 
avian  brain  and  Freund's  adjuvants,  killed  mycobacteria  in  water-in-oil 
emulsion (1).  The pathogenesis of this disorder is thought to be due to delayed 
sensitivity to the brain in association with the adjuvants (2). The evidence for 
this  hypothesis is  not  completely consistent,  the  rabbit  (2-4)  but  not  the 
guinea pig (5)  developing delayed cutaneous hypersensitivity to homologous 
nervous tissue following injection of homologous nervous tissue with adjuvants. 
Since the concentration of antigen in whole brain might be too low to permit 
a visible skin reaction to develop in the guinea pig, experiments were performed 
using partially purified encephalitogenic proteins. These water-soluble proteins 
are approximately 30 times as active as the whole homologous brain from which 
they were extracted by dilute acid after removal of lipids (6).  In these experi- 
ments sensitivity to tuberculin was simultaneously determined 11, 15, 21, and 
28 days after the injection of whole guinea pig brain with adjuvants. The sever- 
ity of  EAE  was  made to vary by using encephalitogenic vaccines containing 
widely differing amounts of killed tubercle bacilli with a  constant amount of 
homologous brain.  The results were  quite  surprising  (Fig.  1):  not only was 
there no convincing evidence of sensitivity to the homologous encephalitogenic 
extract, but also those animals repeatedly skin-tested failed to  develop  sig- 
nificant clinical or histological evidence of the disease. 
Other  investigators  have  reported  that  EAE  can  be  prevented  by  pro- 
treatment of newborn (7-9) or adult (10, 11) animals with incomplete vaccines 
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containing  whole  brain,  encephalitogenic  brain  extracts  (12),  or  tubercle 
bacilli (12,  13). Suppression of the disease subsequent to the injection of the 
complete encephalitogenic vaccine has not  been reported following skin tests 
with whole brain (2-5,  14,  15),  tuberculin (15), or tubercle bacilli (3) or even 
following desensitization  with  whole brain  or  tuberculin  (16).  Condie  el  al. 
(17) have recently reported suppression by the intravenous administration of 
whole brain emulsion to heparinized rabbits 7  days after challenge, but  they 
have not yet reported histological confirmation of their results. 
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Fro. 1. Suppression of EAE by skin tests at ll, 15, 21, and 28 days with acid extract of 
guinea pig brain and PPD. (Experiment 1, Table II; original encephalitngenic  vaccines con- 
tained 0.3 rag. lyophilized  guinea pig brain and various amounts of Mycobac~'rium luberv~dosis. 
Note also range of concentrations  of tubercle bacilli for optimal production Of EAE in guinea 
pigs not skin-tested.) 
Since this was the first demonstration of suppression of EAE so long after 
the injection of encephalitogenic vaccine, further experiments were performed 
to determine whether  the  suppression  was  real  or  some  statistical  artifact, 
whether it was due to the tuberculin, to the brain extract, or to some non-spe- 
cific stress reaction, and whether there was any quantitative relation between 
the amount of antigen and the degree of suppression. 
Method 
In the first 4 experiments encephalitngenic vaccines were made containing 0.5 rag. (dry 
weight) heat-kiUed Mycobavterium tuberculosis and 0.5 rag. (dry weight) lyophilized whole SHAW~ FAHLBERG~ KIES~ AND  ALVORD  173 
guinea pig brain in each 0.1 ml. of emulsion (2 parts Bayol F or heavy mineral oil, 1 part aqua- 
phor, 1 part 0.85 per cent saline). Intradermal injection of 0.1 ml. was made over the sternum. 
Skin test solutions of tuberculin  (generously supplied  as Corper's PPD by  Parke, Davis 
and  Company)  were made in saline, and  of acid extract of guinea pig brain  (6)  in Hanks 
buffered salt solution. Dialysis of the brain extract against cold Hanks solution was carried 
out for 24 to 48 hours followed by centrifugation to clarify the solutions which were of approxi- 
mately neutral pH as indicated the phenol red indicator. Single or multiple intradermal injec- 
tions of 0.1  ml. each were given in the previously shaved skin of the back. The amounts of 
antigens contained in each 0.1 ml. varied as follows: 
PPD: 0.002 to 0.03 mg. 
Acid extract: 0.4 to 0.6 rag.  (representing  about  50  per cent of the original extract,  the 
remainder being insoluble in Hanks  solution after dialysis). 
Skin damage of approximately the same size (1 cm. in diameter) as the above skin tests 
was produced by the intradermal injection of 0.2 ml. of 20 per cent ethanol. 
TABLE I 
Calculation of Disease Index (19) 
Severity of histologic 
disease 
O, ? 
Slight 
Moderate to 
marked 
Severity of clinical disease 
O, ?  Definite 
parslysis 
Killed when 
moribund 
9 
10 
Died 
3 
u* 
7 
10 
Presence of 
lipemis 
0 
+ 
0 
+ 
0 
+ 
* Blood not collected from animals found dead. 
The general design of the first 4 experiments was as follows: white male guinea pigs of mixed 
breed, each weighing about 500 gin., were obtained from May Rabbitry, San Antonio. Groups 
of 50 to 80 animals were injected with a particular encephalitogenic vaccine. Each animal was 
kept in an individual cage randomly arranged in the animal room with respect to each other. 
Subgroups of 5 to 10 animals previously identified by code numbers were injected with the 
skin test solutions on predetermined days (8 to 11, 13 to 15, and sometimes 18 to 21 and 28) 
following the injection of the encephalitogenic vaccine. Uninjected controls were shaved and 
handled the same way but were not skin-tested. Each animal was observed once or twice daily 
for evidence of weakness,  paralysis,  difficulty in righting, fecal impaction,  weight loss,  or 
ruffled  fur. Unless definite weakness or paralysis was noted, the animal was considered only 
questionably involved; but if definite signs followed the development of questionable signs, 
the day of onset was considered to be that of the questionable signs.  If the animal appeared 
moribund, it was killed; in any event all animals were killed on the 30th day, serum collected, 
and perfusion with agar-formalin (18) accomplished. The brain and spinal cord were examined 
in longitudinal sections stained with hematoxylin and eosin after embedding in paraffin. In 
the graphs of the incidence of disease by day of onset, those animals having significant histo- 
logic evidence but not having demonstrated clinical evidence of disease were arbitrarily added 174  SUPPRESSION  OF  "ALLERGIC ~  ENCEPHALOMYELITIS 
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FIo. 2. Effect of skin tests at 11 and 15 days with acid extract of guinea pig brain, PPD, or 
alcohol  (Experiment 2,  Table II). 
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Fxo. 3. Effect of skin tests at 9, 14, and 21 days with larger amounts of acid extract of guinea 
pig brain, PPD, or alcohol (Experiment 3, Table II). SHAW, FAHLBERG, KIES~ AND ALVORD  175 
to the graph on the 30th day. In addition, each animal was scored according to a graded re- 
sponse "disease index"  (19), based on the severity of clinical, hematological, and histological 
abnormalities. Table I  indicates the numerical score given each animal. An average disease 
index was obtained for each group of animals for statistical analysis and comparison. 
Experiments  5 and 6 differed only in the following ways: the encephalitogenlc vaccines 
contained 0.1 rag. Mycobaaerium b'utyricum and 0.3 mg. lyophilized guinea pig brain. "Borate- 
soluble protein" (20) extracted from the acid extract (6) of guinea pig brain was dissolved in 
physiological saline at concentrations of 1 to 5 mg./ml.,  2 intradermal  injections of 0.1 ml. 
being given on the 8th,  13th, and 18th day after the challenge vaccine. Groups of 14 to 30 
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FIG. 4. Effect of skin tests at 9, 14, and 21 days with still larger amounts of acid extract o 
guinea pig brain or PPD (Experiment 4, Table II). 
guinea pigs were obtained  from a  closed colony maintained  at the National  Institutes of 
Health,  Bethesda. 
RESULTS 
The results can best be presented graphically (Figs. 2 to 4) and demonstrate 
that suppression of EAE induced in guinea pigs with whole homologous brain 
and  adjuvants  occurred  regularly  following  intradermal  injections  of  the 
acid extract of guinea pig brain. Furthermore, the more brain extract that was 
given,  the  more  complete  was  the  suppression:  no  statistically  significant 
suppression occurred when 0.5 rag. was given on the llth and 15th day (Fig. 2), 
but  practically  complete  suppression  occurred  when  5  such  injections  were 
given on each of the 9th, 14th, and 21st days (Fig. 4). 
A  non-specific stress,  such  as provided  by the  intradermal  injection  of 20 176  SUPPRESSION OF  "ALLERGIC"  ENCEPHALOMYELITIS 
per  cent  alcohol  in  amounts  which  produced  approximately  the  same  size 
skin reaction but  with central necrosis, did not produce suppression of EAE 
TABLE II 
Suppression of EAE by Acid Extract, of Guinea Pig Brain, Alcohol or PPD after Challenge with 
Whole Guinea Pig Brain and Adjuvants* 
No. 
1 
2 
3  0 
0 
0 
0 
0.5, 0.5, 
4 
Amount and No. of intradermal injections of 
Acid extract  PPD  Alcohol 
mg 
0 
0.5, 0.05 
0 
0 
0 
0.5 
0.5 
0.1, 0.02 
0 
0 
0 
0.5, 0.25 
0.5, 0.25 
0.5X5 
ug 
0 
2, 0.2 
0 
0 
2, 2 
20, 20, 2, 0.2 
0 
0 
5, 2.5 
30X  5 
5, 2.5 
0 
0 
0 
X1 
0 
0 
0 
0 
X2 
0 
0 
0 
On days after  Clinical  Disease index 
challenge*  EAE~  ± standard  error of mean 
0  4/5  7.6  4-  1.5 
11, 15, 21, 28  0/5  1.0  4- 0.8 
0  6/8  7.0  4-  1.1 
11, 15  6/8  7.5  .4-  1.3 
11, 15  4/8  5.6  ±  1.6 
11, 15  4/8  5.1  4-  1.6 
11, 15  4/8  5.4  4-  1.6 
0  6/10  6.1  4-  1.4 
9, 14, 21  5/10  5.2  4-  1.4 
9, 14, 21  6/10  5.3  4-  1.4 
9, 14, 21  2/7  3.3  4-  1.3 
9, 14, 21  3/10  3.1  -4-  1.3 
0  6/10  4.0  .-i- 1.0 
9, 14, 21  3/9  3.4  -4-  1.3 
9, 14, 21  6/10  5.5  -4-  1.5 
9, 14, 21  3/10  3.2  ±  1.0 
9, 14, 21  0/10  0.8  4-  0.4 
9, 14, 21  0/10  O. 1 4-  O. 1 
* Encephalitogenic vaccine in experiment 1 contained 0.3 mg. brain and 0.9 rag. My¢o- 
bacterium tuberculosis; all other groups were injected with vaccines containing 0.5 rag. of each 
in 0.1 ml. injected intradermally over the sternum. 
~t Numerator is number of guinea pigs with clinical EAE  (definite  paralysis), and  de- 
nominator is number of animals injected. 
(Figs.  2  and  3),  and  only  inconstant  effects  were  obtained  with  tuberculin 
(PPD). 
The results of these and other similar experiments are summarized in Table 
II. 
A  similar series of  experiments  was  performed  using  as  skin  test  antigen 
that  portion of the acid  extract of  guinea  pig brain  which is soluble in a  pH 
9  borate buffer.  Recent evidence indicates that this soluble portion ("borate- 
soluble protein") has an even greater encephalitogenic activity than  the acid SHAW~ FAHLBERG,  KIES~  AND  ALVORD  177 
extract (20). Experiment 5 (Table III) with whole brain as the inciting material 
and borate-soluble protein ("BSP") as the skin test material showed complete 
suppression  of clinical signs of disease. However,  the histologic and  clinical 
results were not well correlated in this series; i.e.,  6 out of 7 of the treated 
animals showed mild but definite inflammatory lesions. In spite of this, the 
disease index of the treated series was significantly less than that of the controls 
(3.4 as compared to 8.0).  There is at the moment no explanation for the lack 
of correlation between clinical and histological results in this series. Experiment 
6 repeated and extended these results by testing simultaneously a smaller dose 
of "BSP" and by omitting 1 or 2 of the 3 skin tests. It is evident that 1 rag. of 
TABLE  III 
Suppression of EAE by Skin Tests with "Borate-Soluble Protein"  (BSP) after Challenge with 
Whole Guinea Pig Brain and Adjutants* 
Disease index q-  Exl~i~.  ent  BSP  On days after  Clinical EAE~  standard error of mean  •  challenge* 
mg. 
0 
0.5X2 
0 
0.1X2 
0.5X2 
0.5X2 
0.5X2 
0 
8, 13, 18 
0 
8, 13, 18 
8 
8, 13 
8, 13, 18 
o/¢ 
4/6 
3/6 
4/6 
3/6 
0/6 
8.0  -4-  1.0 
3.4  .4-  0.6 
6.0  .4-  1.7 
4.8  -4-  1.6 
4.5  -4-  1.4 
5.0  -4-  1.4 
0.7  -4-  0.2 
* Encephalitogenic vaccine contained 0.3  rag.  of brain and  0.1  rag. Mycobazteriura bu- 
t~icura in 0.1 ml. injected intradermally over sternum• 
~; Numerator  is number of  guinea pigs with clinical EAE  (definite paralysis),  and  de- 
nominator is number of animals injected. 
"BSP"  injected intradermally on each of 3  days following the initial whole 
brain injection suppressed the disease clinically and decreased the severity of 
histological lesions. One or 2 such injections were not sufficient to alter the 
disease significantly, nor was 0.2 mg. injected 3 different times adequate for 
suppression. 
It may be added that there was no systemic reaction to  the intradermal 
injection of even large amounts of either PPD or neural extracts. Furthermore, 
the cutaneous reactions  to  the  neural  extracts did not  differ in  appearance 
from those in normal controls (21). 
DISCUSSION 
The results of  the present experiments indicate that suppression of EAE 
induced by previous injection of whole homologous brain in Freund's adjuvants 
can be produced by skin-tests with relatively large amounts of aqueous solutions 178  SUPP1LESSION  OF  ~ALLERGIC" ENCEPHALOMYELITIS 
of the same chemical  component of homologous brain which  most effectively 
produces  the disease when mixed  with  Freund's  adjuvants.  The  inconstant 
suppressive effects of tuberculin are most easily attributed to statistical vari- 
ations which occur commonly in biological systems. 
Although the vaccines were prepared on  the basis of previous experiments 
(19) to produce maximal disease with an average disease index of about 8, the 
present results in the controls were generally not quite so great (disease indices 
of 6.0  to 8.0);  and  in the particular  experiment  (Fig.  4) in  which  the  most 
complete suppression occurred the encephalitogenic  vaccine seemed the least 
effective (disease  index of only 4.0).  The reasons for this variation from the 
expected results in the controls are certainly not dear. It is quite likely, how- 
ever, regardless  of whether EAE is due to hypersensitivity or not,  that  the 
immunologic  events developing in the treated animal are quite complicated: 
not only must there be some competition of the many antigens in the original 
encephalitogenic  vaccine (tubercle bacilli and whole brain) with the production 
of many circulating  antibodies and  tissue hypersensitivities,  but in addition 
there must be some competition between the encephalitogenic  power of the 
vaccine containing whole brain and the suppressive ability of the brain  extract 
which contains relatively few neural proteins. In such a complicated biological 
system one must await further  experiments before any definitive conclusions 
can be drawn,  but one may anticipate  that  more complete suppression  will 
be obtained if the original  encephalitogenic vaccine and the skin test solution 
contain  the same neural extract,  that  better routes and  timing of the treat- 
ments will be found, and that the interrelationships between the many chemical 
components of whole brain and their ability to produce EAE may be demon- 
strated by the suppressive ability of each individually or in combination. 
A distinction probably should be made between prevention, suppression, and 
therapy of  EAE:  prevention by  treatments  given  before  the  injection  and 
suppression by treatments  given  after  the  injection  of the  encephalitogenic 
vaccine, and therapy by treatments  given after the onset of clinical  evidence 
of disease.  These distinctions  are admittedly arbitrary,  and  the mechanisms 
underlying these 3 phenomena may or may not be identical or related. There 
are probably several different immunologic  mechanisms underlying Wevention 
(22): immunologic  tolerance  (7),  circulating  protective or blocking  anti-brain 
antibodies (reference  23, but not reference 24), and a  Koch reaction (13, 25). 
Several other non-immunological  methods have been used to prevent and/or 
to suppress EAE: x-irradiation,  cortisone (26, 27), ACTH (28), salicylate and 
para-aminobenzoic acid (29), not always successfully (30, 31). 
According  to  these  arbitrary  definitions,  the  present  experiments  are 
considered  to represent  suppression, rather than prevention or therapy. The 
lack  of  suppression  by  intradermal  injections  of  dilute  alcohol  producing 
comparable cutaneous lesions  indicates  that the suppression by the encepha- 
litogenic  neural  proteins  is  not due  to a  non-specific  stress reaction (9), but SHAW,  FAHLBERG~  KIES,  AND  ALVORD  179 
unfortunately no  further  conclusions are  warranted  at  this  time as  to  the 
specificity of suppression for encephalitogenic as compared to non-encephalit- 
ogenic extracts of brain or as to the pathogenesis  of  the  suppression.  Some 
clue concerning the pathogenesis may be afforded by the quantitative data, 
which indicates that the greater the amount of active extract given, the more 
suppression  is  produced,  and  which  suggest  some  specific  desensitization, 
deflection, or  neutralization of antibodies,  or paralysis of antibody-forming 
mechanisms.  If  suppression  is  on an  immunologic basis,  however,  it  seems 
strange that the skin reaction was no greater than that which occurred in con- 
trols (21). 
SUMMARY 
The intradermal injection of aqueous solutions of certain homologous neural 
proteins will suppress  the encephalomyelitis which is induced in guinea pigs 
by the previous injection of whole homologous brain with Freund's adjuvants. 
These  neural  proteins  extracted  by  dilute  acid  from  defatted  guinea  pig 
brain are themselves highly encephalitogenic when injected with adjuvants, 
but  the  specificity of  this  suppression  for encephalitogenic as compared to 
non-encephalitogenic extracts remains to be proven. 
Suppression is probably not due to a non-specific stress reaction, as indicated 
by the absence  of suppression  by intradermal injections of  alcohol and  by 
statistically insignificant and inconstant effects of similar injections of tuber- 
culin. 
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